Skip to main content

Advertisement

SpringerLink
Log in

Tumor mRNA–loaded dendritic cells elicit tumor-specific CD8+ cytotoxic T cells in patients with malignant glioma

  • Original Article
  • Published:
Cancer Immunology, Immunotherapy Aims and scope Submit manuscript

Abstract

In this study, we demonstrate that tumor mRNA–loaded dendritic cells can elicit a specific CD8+ cytotoxic T-lymphocyte (CTL) response against autologous tumor cells in patients with malignant glioma. CTLs from three patients expressed strong cytolytic activity against autologous glioma cells, did not lyse autologous lymphoblasts or EBV-transformed cell lines, and were variably cytotoxic against the NK-sensitive cell line K-562. Also, DCs-pulsed normal brain mRNA failed to induce cytolytic activity against autologous glioma cells, suggesting the lack of autoimmune response. Two patients' CD8+ T cells expressed a modest cytotoxicity against autologous glioma cells. CD8+ T cells isolated during these ineffective primings secreted large amounts of IL-10 and smaller amounts of IFN-γ as detected by ELISA. Type 2 bias in the CD8+ T-cell response accounts for the lack of cytotoxic effector function from these patients. Cytotoxicity against autologous glioma cells could be significantly inhibited by anti-HLA class I antibody. These data demonstrate that tumor mRNA–loaded DC can be an effective tool in inducing glioma-specific CD8+ CTLs able to kill autologous glioma cells in vitro. However, high levels of tumor-specific tolerance in some patients may account for a significant barrier to therapeutic vaccination. These results may have important implications for the treatment of malignant glioma patients with immunotherapy. DCs transfected with total tumor RNA may represent a method for inducing immune responses against the entire repertoire of glioma antigens.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1.
Fig. 2.

Similar content being viewed by others

References

  1. Anichini A, Mortarini R, Maccalli C, Squarcina P, Fleischhauer K, Mascheroni L, Parmiani G (1996) Cytotoxic T cells directed to tumor antigens not expressed on normal melanocytes dominate HLA-A2.1-restricted immune repertoire to melanoma. J Immunol 156:208

    CAS  PubMed  Google Scholar 

  2. Aoki H, Mizuno M, Natsume A, Tsugawa T, Tsujimura K, Takahashi T, Yoshida J (2001) Dendritic cells pulsed with tumor extract-cationic liposome complex increase the induction of cytotoxic T lymphocytes in mouse brain tumor. Cancer Immunol Immunother 50:463

    Article  CAS  PubMed  Google Scholar 

  3. Ashley DM, Faiola B, Nair S, Hale LP, Bigner DD, Gilboa E (1997) Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induce antitumor immunity against central nervous system tumors. J Exp Med 186:1177

    CAS  PubMed  Google Scholar 

  4. Boczkowski D, Nair SK, Snyder D, Gilboa E (1996) Dendritic cells pulsed with RNA are potent antigen presenting in vitro and in vivo. J Exp Med 184:465

    CAS  PubMed  Google Scholar 

  5. Castelli C, Storkus WJ, Maeurer MJ, Martin DM, Huang EC, Pramanik BN, Nagabhushan TL, Parmiani G, Lotze MT (1996) Mass spectrometric identification of a naturally processed melanoma peptide recognized by CD8+ T cells. J Exp Med 181:363

    Google Scholar 

  6. Cox AL, Skipper J, Chen Y, Henderson RA, Darrow TL, Shabanowitz J, Engelhard VH, Hunt DF, Slingluff CL (1994) Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. Science 264:716

    PubMed  Google Scholar 

  7. Dranoff G, Jaffee E, Lazenby A, Golumbek P, Levitsky H, Brose K, Jackson V, Hamada H, Pardoll D, Mulligan RC (1993) Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 90:3539

    CAS  PubMed  Google Scholar 

  8. Ghosh P, Komschlies KL, Cippitelli M, Longo DL, Subleski J, Ye J, Sica A, Young HA, Wiltrout RH, Ochoa AC (1995) Gradual loss of T-helper 1 populations in spleen of mice during progressive tumor growth. J Natl Cancer Inst 87:1478

    CAS  PubMed  Google Scholar 

  9. Heimberger AB, Crotty LE, Archer GE, McLendon RE, Friedman A, Dranoff G, Bigner DD, Sampson JH (2000) Bone marrow-derived dendritic cells pulsed with tumor homogenate induce immunity against syngeneic intracerebral glioma. J Neuroimmunol 103:16

    Article  CAS  PubMed  Google Scholar 

  10. Insug O, Ku G, Ertl HC, Blaszczyk-Thurin M (2002) A dendritic cell vaccine induces protective immunity to intracranial growth of glioma. Anticancer Res 22:613

    CAS  PubMed  Google Scholar 

  11. Kikuchi T, Akasaki Y, Irie M, Homma S, Abe T, Ohno T (2001) Results of a phase I clinical trial of vaccination of glioma patients with fusions of dendritic and glioma cells. Cancer Immunol Immunother 50:337

    Article  CAS  PubMed  Google Scholar 

  12. Liau LM, Black KL, Prins RM, Sykes SN, DiPatre PL, Cloughesy TF, Becker DP, Bronstein JM (1999) Treatment of intracranial gliomas with bone marrow-derived dendritic cells pulsed with tumor antigens. J Neurosurg 90:1115

    CAS  PubMed  Google Scholar 

  13. Nair SK, Snyder D, Rouse BT, Gilboa E (1997) Regression of tumors in mice vaccinated with professional antigen-presenting cells pulsed with tumor extracts. Int J Cancer 70:706

    CAS  PubMed  Google Scholar 

  14. Nair SK, Boczkowski D, Morse M, Cumming RI, Lyerly HK, Gilboa E (1998) Induction of primary carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes in vitro using human dendritic cells transfected with RNA. Nat Biotechnol 16:364

    CAS  PubMed  Google Scholar 

  15. Peoples GE, Goedegeboure PS, Smith R, Linehan DC, Yoshino I, Eberlein TJ (1995) Breast and ovarian-cancer specific cytotoxic T lymphocytes recognize the same HER/2neu-derived peptide. Proc Natl Acad Sci USA 92:432

    CAS  PubMed  Google Scholar 

  16. Romagnani S (1992) Human TH1 and TH2 subsets: regulation of differentiation and role in protection and immunopathology. Int Arch Allergy Immunol 98:279

    CAS  PubMed  Google Scholar 

  17. Romani N, Gruner S, Brang D, Kampgen E, Lenz A, Trockebacher B, Konwalinka GO, Fritsch P, Steinman RM, Schuler G (1994) Proliferating dendritic cell progenitors in human blood. J Exp Med 180:83

    CAS  PubMed  Google Scholar 

  18. Sampson JH, Archer GE, Ashley DM, Fuchs HE, Hale LP, Dranoff G, Bigner DD (1996) Subcutaneous vaccination with irradiated, cytokine-producing tumor cells stimulates CD8+ cell-mediated immunity against tumors located in the "immunologically privileged" central nervous system. Proc Natl Acad Sci USA 93:10399

    Article  CAS  PubMed  Google Scholar 

  19. Steinman RM (1991) The dendritic cell system and its role in immunogenicity. Ann Rev Immunol 9 : 271

    CAS  Google Scholar 

  20. Yamanaka R, Zullo SA, Tanaka R, Blaese M, Xanthopoulos KG (2001) Enhancement of antitumor immune response in glioma models in mice by genetically modified dendritic cells pulsed with Semliki forest virus-mediated complementary DNA. J Neurosurg 94:474

    CAS  PubMed  Google Scholar 

  21. Yoshino I, Goedegeboure PS, Peoples GE, Parikh AS, DiMain JM, Lyerly HK, Gazdar AF, Eberlein TJ (1994) HER2/neu-derived peptides are shared antigens among human non-small cell lung cancer and ovarian cancer. Cancer Res 54:3387

    CAS  PubMed  Google Scholar 

  22. Young JW, Inaba K (1996) Dendritic cells as adjuvants for class I major histocompatibility complex-restricted antitumor immunity. J Exp Med 183:7

    CAS  PubMed  Google Scholar 

  23. Yu JS, Wheeler CJ, Zeltzer PM, Ying H, Finger DN, Lee PK, Yong WH, Incardona F, Thompson RC, Riedinger MS, Zhang W, Prins RM, Black KL (2001) Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration. Cancer Res 61: 842

    CAS  PubMed  Google Scholar 

  24. Zitvogel L, Majordomo JI, Tjandrawan T, DeLeo AB, Clarke MR, Lotze MT, Storkus WJ (1996) Therapy of murine tumors with tumor peptide-pulsed dendritic cells:dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines. J Exp Med 183:87

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurosurgery, Brain Research Institute, Niigata University, Asahimachi-dori 1-757, 951-8585, Niigata City, Japan

    Tsutomu Kobayashi, Ryuya Yamanaka, Junpei Homma, Naoto Tsuchiya, Naoki Yajima & Ryuichi Tanaka

  2. Department of Neurosurgery, Niigata Cancer Center Hospital, Niigata, Japan

    Seiichi Yoshida

Authors
  1. Tsutomu Kobayashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ryuya Yamanaka
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Junpei Homma
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Naoto Tsuchiya
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Naoki Yajima
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Seiichi Yoshida
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Ryuichi Tanaka
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ryuya Yamanaka.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kobayashi, T., Yamanaka, R., Homma, J. et al. Tumor mRNA–loaded dendritic cells elicit tumor-specific CD8+ cytotoxic T cells in patients with malignant glioma. Cancer Immunol Immunother 52, 632–637 (2003). https://doi.org/10.1007/s00262-003-0408-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00262-003-0408-5

Keywords

Search

Navigation